» Articles » PMID: 12239142

Immunophenotypic Clustering of Myelodysplastic Syndromes

Abstract

Myelodysplastic syndromes (MDSs) are heterogeneous diseases of bone marrow (BM) cell precursors for which immunophenotypic characterization is still considered irrelevant despite the accuracy and sensitivity of flow cytometry techniques. The aim of this study was to determine whether immunophenotypic abnormalities could be defined in MDSs and could correlate with the French-American-British classification and cytogenetics. Analysis was performed on 275 BM samples (207 MDS patients, 68 controls) and 25 control blood samples. Immunophenotyping was based on a primary gating of blast cells, monocytes, and granulocytes according to CD45 antigen expression and side scatter light diffraction. Immunophenotypic hierarchical clustering was performed to analyze the results. The data obtained show that (1) immunophenotypic clustering partly discriminates patients with refractory anemia with excess blasts/refractory anemia with excess blasts in transformation (RAEB/RAEB-T), chronic myelomonocytic leukemia (CMML), and refractory anemia/refractory anemia with ring sideroblasts (RA/RARS) for CD45(lo) blast cells and patients with RA/CMML, RARS, and RAEB/RAEB-T for CD45(hi)/side scatter(hi) (SS(hi)) granulocytes; (2) the most discriminating markers were CD16, CD34, CD36, CD38, CD71, and HLA-DR for blast cells and CD11b, CD13, CD33, CD36, CD38, CD71, and HLA-DR for CD45(hi)/SS(hi) granulocytes; (3) clusters related to CD34 expression were associated with high levels of blast cells on BM smear; (4) clusters related to high levels of CD36 expression on CD45(lo) blast cells and CD45(hi)/SS(hi) granulocytes were associated with a poor International Prognosis Scoring System score; and (5) high levels of CD71 expression on CD45(hi)/SS(hi) granulocytes were associated with the RARS category. These results show a close relationship between immunophenotypic abnormalities and BM dysplasia and suggest that flow cytometry could be a future tool for the characterization of MDSs.

Citing Articles

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.

Zhang L, Deeb G, Deeb K, Vale C, Peker Barclift D, Papadantonakis N Cancers (Basel). 2024; 16(8).

PMID: 38672585 PMC: 11048433. DOI: 10.3390/cancers16081503.


Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman-Diamond syndrome cells.

Cipolli M, Boni C, Penzo M, Villa I, Bolamperti S, Baldisseri E Br J Haematol. 2023; 204(1):292-305.

PMID: 37876306 PMC: 10843527. DOI: 10.1111/bjh.19134.


Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.

Porwit A, Bene M, Duetz C, Matarraz S, Oelschlaegel U, Westers T Cytometry B Clin Cytom. 2022; 104(1):27-50.

PMID: 36537621 PMC: 10107708. DOI: 10.1002/cyto.b.22108.


Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India.

Dhingra G, Dass J, Arya V, Gupta N, Saraf A, Langer S Indian J Med Res. 2020; 152(3):254-262.

PMID: 33107485 PMC: 7881827. DOI: 10.4103/ijmr.IJMR_924_18.


Profiling myelodysplastic syndromes by mass cytometry demonstrates abnormal progenitor cell phenotype and differentiation.

Behbehani G, Finck R, Samusik N, Sridhar K, Fantl W, Greenberg P Cytometry B Clin Cytom. 2020; 98(2):131-145.

PMID: 31917512 PMC: 9292828. DOI: 10.1002/cyto.b.21860.